Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Phathom's accomplishments in 2023 were nothing short of amazing and I'm extremely proud of this team |
| So what we see is that the utilization of BlinkRx is growing over time which is exactly what we intended and we communicated to you all and are strongly communicating to physicians that it's the best opportunity for insured patient gets access to VOQUEZNA |
| So the -- so Chase, I would say that the confidence that scripts will go through for Express Scripts national formulary, is we're absolutely confident of that |
| Today, I'm proud to share that we're delivering on those goals prescribers have quickly recognized the VOQUEZNA's differentiated and novel mechanism of action |
| is off to a strong start and we remain steadfast in delivering on our strategy of driving blockbuster potential through continued market expansion |
| After over 30 years since the first PPI was approved, there is strong demand for something new |
| Our goal there was really to make sure that, first of all, customers had a good experience |
| We are successfully executing our launch strategy with continued promotion of physicians, a broadened consumer campaign and expanded commercial coverage; we anticipate significant growth in filled prescriptions over the course of 2024 |
| We are confident in our strategy and believe it will continue to yield expanded coverage, resulting in an uptick in filled prescriptions throughout the remainder of 2024 |
| In that short period, we've achieved many regulatory, manufacturing, financial and commercial milestones demonstrating the significant experience and dedication of our teams |
| In fact, with our recent Express Scripts win, we're well on our way to securing widespread coverage for commercial patients |
| These early indicators, along with vonoprazan's massive commercial success in Japan have reinforced my belief in VOQUEZNA's bright future here in the U.S |
| adults, positive feedback from physicians and patients and anticipated label expansions |
| We remain confident in our belief that VOQUEZNA has the potential to reach annual peak revenues of greater than $3 billion |
| We've made great progress on that front so far and anticipate expanded commercial coverage throughout the year |
| Although this has led to a proportion of early VOQUEZNA prescriptions not being filled, we believe we are well positioned to convert more of these scripts over time |
| So I feel really confident about our best case and very hopeful that we can also get that additional PA |
| We believe our ability to obtain commercial formulary replacement with one of the nation's largest PBM so quickly after approval indicates that our pricing and access strategy is resonating well with payers |
| So we see that this is -- we really were successful in getting the broadest population possible |
| If approved, this indication will significantly broaden VOQUEZNA's addressable population and we believe further accelerate uptake |
| We believe vonoprazan's unique MOA bode well for success in these 2 trials |
| We're really pleased with the demand |
| Among those writers, we are already seeing repeat prescribing which builds our confidence that physicians recognize VOQUEZNA's value for patients |
| Overall, we believe our strong balance sheet will enable us to continue delivering on our launch and development strategies |
| As our reps continue to promote to physicians and garner the backing of strengthened commercial coverage, we expect positive script momentum to continue |
| The qualitative feedback from these early months of launch has bolstered our belief that these elements are present in the GERD market |
| In closing, I'm extremely happy with the commentary we're hearing from prescribers and how it translates into demand |
| As for the back half of 2024, we believe the planned launch of Non-Erosive GERD daily dosing in July, pending FDA approval, will serve as another key catalyst for driving adoption |
| So we're finalizing the protocol for the Eosinophilic Esophagitis Phase II, we're really excited about that |
| We believe VOQUEZNA represents a blockbuster opportunity and this launch is off to an exciting start |
| Statement |
|---|
| Actual results can materially differ from the forward-looking statements and any such risks can materially adversely affect the business, the results of operations and trading prices for Phathom's common stock |
| First, could you remind us, there was some confusion on whether the uptick in IMS, especially was observed in January, -- was that a function of IMS just doing a better job capturing Blink? Or was that completely exclusive? Maybe a different way of answering that is the significant sort of acceleration we saw almost tripling in TRx heading into January, February |
| Turning to EPS; we reported GAAP net loss for the fourth quarter 2020 of $79.6 million or $1.39 loss per share compared to $55 million or $1.33 and loss per share for the fourth quarter 2022 |
Please consider a small donation if you think this website provides you with relevant information